Cargando…

S3.1 Are there ERT defined guidelines for Pompe disease?

Detalles Bibliográficos
Autores principales:	Toscano, Antonio, Barca, Emanuele, Musumeci, Olimpia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Pacini Editore SpA 2011
Materias:	Session 3. the Network of Specialists
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3298103/

Ejemplares similares

S3.2 The role of Patients Association (Italian Glycogenosis Association)
por: Martino, L.
Publicado: (2011)

S2.3 Therapeutic approaches in the late onset form of GSD II
por: Musumeci, Olimpia, et al.
Publicado: (2011)

Enzyme replacement therapy (ERT) in pompe disease
por: Fiumara, Agata
Publicado: (2014)

The Obstetrician/Gynecologist
por: Thorp, John M., et al.
Publicado: (1994)

The General Internist
por: O’Connor, Patrick G.
Publicado: (1994)

The Pediatrician
por: Adger, Hoover, et al.
Publicado: (1994)

The Family Physician
por: Barry, Kirsten L., et al.
Publicado: (1994)

Post-viral olfactory loss and parosmia
por: Liu, Zhen Yu, et al.
Publicado: (2023)

Polycystic ovary syndrome: pathophysiology and therapeutic opportunities
por: Dong, Jiawen, et al.
Publicado: (2023)

Stillbirth: prevention and supportive bereavement care
por: Atkins, Bethany, et al.
Publicado: (2023)

T cell immune memory after covid-19 and vaccination
por: Wang, Lulu, et al.
Publicado: (2023)

Early is better? A new algorithm for early diagnosis in Late Onset Pompe Disease (LOPD)
por: TOSCANO, ANTONIO, et al.
Publicado: (2013)

Safety outcomes and patients’ preferences for home-based intravenous enzyme replacement therapy (ERT) in pompe disease and mucopolysaccharidosis type I (MPS I) disorder: COVID-19 and beyond
por: Toscano, Antonio, et al.
Publicado: (2023)

Immune Responses and Hypercoagulation in ERT for Pompe Disease Are Mutation and rhGAA Dose Dependent
por: Nayak, Sushrusha, et al.
Publicado: (2014)

S1.3 Adult-onset Pompe disease
por: Di Iorio, Giuseppe, et al.
Publicado: (2011)

CRIM-negative infantile Pompe disease: Characterization of immune responses in patients treated with ERT monotherapy
por: Berrier, Kathryn L., et al.
Publicado: (2015)

Effect of enzyme replacement therapy (ERT) added to Home Mechanical Ventilation (HMV) in Adult Pompe disease
por: Sayeed, Nadia, et al.
Publicado: (2015)

Positive Impact of Home ERT for Mucopolysaccharidoses and Pompe Disease: The Lesson Learnt from the COVID-19 Pandemic
por: Fiumara, Agata, et al.
Publicado: (2023)

S1.1 Introductory notes to Pompe disease and aims of the Meeting
por: Sampaolo, Simone, et al.
Publicado: (2011)

L-alanine supplementation in Pompe disease (IOPD): a potential therapeutic implementation for patients on ERT? A case report
por: Rovelli, Valentina, et al.
Publicado: (2022)

Successful twin pregnancy in a 38-year-old woman with Pompe disease despite interruption of enzyme replacement therapy (ERT)
por: Tiling, N, et al.
Publicado: (2013)

Non-depleting anti-CD4 monoclonal antibody induces immune tolerance to ERT in a murine model of Pompe disease
por: Sun, Baodong, et al.
Publicado: (2014)

Low-Dose Liver-Targeted Gene Therapy for Pompe Disease Enhances Therapeutic Efficacy of ERT via Immune Tolerance Induction
por: Han, Sang-oh, et al.
Publicado: (2017)

Low-Dose Liver-Targeted Gene Therapy for Pompe Disease Enhances Therapeutic Efficacy of ERT via Immune Tolerance Induction
por: Han, Sang-oh, et al.
Publicado: (2019)

Enzyme Replacement Therapy (ERT) on Heart Function Changes the Outcome in Patients with Infantile-Onset Pompe Disease: A Familial History
por: Lecis, Marco, et al.
Publicado: (2023)

A genetic modifier of symptom onset in Pompe disease
por: Bergsma, Atze J., et al.
Publicado: (2019)

Evaluation of muscle biopsy in late-onset GSDII patients before and after enzyme replacement therapy (ERT)
por: Violano, R, et al.
Publicado: (2013)

Pompe disease diagnosis and management guideline
por: Kishnani, Priya S., et al.
Publicado: (2006)

Vacuolated PAS-Positive Lymphocytes on Blood Smear: An Easy Screening Tool and a Possible Biomarker for Monitoring Therapeutic Responses in Late Onset Pompe Disease (LOPD)
por: Parisi, Daniela, et al.
Publicado: (2018)

A guide to null models for animal social network analysis
por: Farine, Damien R.
Publicado: (2017)

O.3.1-2 Contribution of a set of physical activity types for adherence to the Dutch Physical Activity Guidelines
por: Kolkman, Japke, et al.
Publicado: (2023)

S2.5 The nutritional approach to Pompe disease
por: Esposito, Katia, et al.
Publicado: (2011)

Childhood Pompe disease: clinical spectrum and genotype in 31 patients
por: van Capelle, C. I., et al.
Publicado: (2016)

Guidelines for vaccinations of a normal child in India
Publicado: (2016)

S2.1 Enzyme replacement therapy (ERT) in Glycogen Storage Disease Type II: the first treatment developed
por: Angelini, Corrado, et al.
Publicado: (2011)

The protective effect of rheumatic disease agents in COVID-19
por: Valenzuela-Almada, María O., et al.
Publicado: (2021)

STIG study: real-world data of long-term outcomes of adults with Pompe disease under enzyme replacement therapy with alglucosidase alfa
por: Gutschmidt, Kristina, et al.
Publicado: (2021)

Algorithm for the Early Diagnosis and Treatment of Patients with Cross Reactive Immunologic Material-Negative Classic Infantile Pompe Disease: A Step towards Improving the Efficacy of ERT
por: Banugaria, Suhrad G., et al.
Publicado: (2013)

Editorial: Fractals in the diagnosis and treatment of the retina and brain diseases
por: Zueva, Marina V., et al.
Publicado: (2022)

Final report on oxide target prototype - Deliverable D3
por: S. Fernandes, E. Bouquerel, L. Bruno, R. Catherall, T. Giles, P. Kasprowicz, J. Lettry, S. Marzari, E. Noah, T. Stora, P. Bricault, M. Dombsky, F. Ames
Publicado: (14/0)

Cannot write session to /tmp/vufind_sessions/sess_oiqnllood3edqhue8ma6bj7mo4